Empyrean Capital Partners Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
AGN
Allergan Inc
AGN
|
+$77.8M |
| 2 |
Williams Companies
WMB
|
+$71.8M |
| 3 |
AGN
Allergan plc
AGN
|
+$65.8M |
| 4 |
PARA
Paramount Global Class B
PARA
|
+$59.5M |
| 5 |
BRCM
BROADCOM CORP CL-A
BRCM
|
+$58.7M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Visa
V
|
+$47.1M |
| 2 |
Dover
DOV
|
+$36.2M |
| 3 |
Vodafone
VOD
|
+$32.8M |
| 4 |
DISCK
Discovery, Inc. Series C Common Stock
DISCK
|
+$28.1M |
| 5 |
B
Barrick Mining
B
|
+$17.8M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Miscellaneous | 56.89% |
| 2 | Healthcare | 12.59% |
| 3 | Energy | 8.63% |
| 4 | Communication Services | 5.31% |
| 5 | Materials | 4.28% |
Similar funds
Empyrean Capital Partners's Q2 2014 Portfolio in Review
As of Q2 2014, Empyrean Capital Partners held 67 positions worth $2.84B, up 8.4% from $2.62B the previous quarter. Its ten largest holdings account for 60% of the portfolio.
Empyrean Capital Partners deployed $232M of net new capital in Q2 2014, opening 27 new positions and adding to 4 existing holdings. Its largest new stake was Allergan Inc: 500,000 shares worth $84.6M.
By sector, the portfolio is most concentrated in Miscellaneous at 57% of assets, down from 71% a quarter earlier, followed by Healthcare and Energy.
On the sell side, the largest reduction was Liberty Media Series A, an estimated $10.3M trimmed.
- Empyrean Capital Partners's largest Q2 2014 buy was Allergan Inc: 500,000 shares worth $84.6M.
- Empyrean Capital Partners added most to UnitedHealth in Q2 2014, an estimated $46M increase.
- Empyrean Capital Partners's biggest Q2 2014 reduction was Liberty Media Series A, cutting an estimated $10.3M.
- Empyrean Capital Partners fully exited Visa in Q2 2014, selling an estimated $47.1M.
- Empyrean Capital Partners's ten largest holdings make up 60% of its $2.84B portfolio in Q2 2014.
- Empyrean Capital Partners opened 27 new positions and closed 14 in Q2 2014.
- Empyrean Capital Partners's portfolio value rose 8.4% quarter-over-quarter to $2.84B.
Based on Empyrean Capital Partners's 13F filing for Q2 2014, filed 14 Aug 2014.